Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
27 10 2020
Historique:
received: 06 04 2020
accepted: 11 09 2020
entrez: 27 10 2020
pubmed: 28 10 2020
medline: 15 5 2021
Statut: ppublish

Résumé

Colony-stimulating factor 3 receptor (CSF3R) encodes the receptor for granulocyte colony-stimulating factor (G-CSF), a cytokine vital for granulocyte proliferation and differentiation. Acquired activating heterozygous variants in CSF3R are the main cause of chronic neutrophilic leukemia, a hyperproliferative disorder. In contrast, biallelic germ line hypomorphic variants in CSF3R are a rare cause of severe congenital neutropenia, a hypoproliferative condition. The impact of heterozygous germ line CSF3R variants, however, is unknown. We identified CSF3R as a new germ line hematologic malignancy predisposition gene through analysis of 832 next-generation sequencing tests conducted in 632 patients with hematologic malignancies. Among germ line CSF3R variants, 3 were abnormal in functional testing, indicating their deleterious nature. p.Trp547* was identified in 2 unrelated men with myelodysplastic syndromes diagnosed at 76 and 33 years of age, respectively. p.Trp547* is a loss-of-function nonsense variant in the extracellular domain that results in decreased CSF3R messenger RNA expression and abrogation of CSF3R surface expression and proliferative responses to G-CSF. p.Ala119Thr is a missense variant found in 2 patients with multiple myeloma and acute lymphoblastic leukemia, respectively. This variant is located between the extracellular immunoglobulin-like and cytokine receptor homology domains and results in decreased G-CSF sensitivity. p.Pro784Thr was identified in a 67-year-old man with multiple myeloma. p.Pro784Thr is a missense variant in the cytoplasmic domain that inhibits CSF3R internalization, producing a gain-of-function phenotype and G-CSF hypersensitivity. Our findings identify germ line heterozygous CSF3R variants as risk factors for development of myeloid and lymphoid malignancies.

Identifiants

pubmed: 33108454
pii: S2473-9529(20)31921-2
doi: 10.1182/bloodadvances.2020002013
pmc: PMC7594406
doi:

Substances chimiques

CSF3R protein, human 0
Receptors, Colony-Stimulating Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5269-5284

Informations de copyright

© 2020 by The American Society of Hematology.

Références

Leuk Res. 1996 Aug;20(8):629-31
pubmed: 8913314
Front Biosci. 2007 Jan 01;12:800-15
pubmed: 17127321
Cancer Genet. 2019 Jun;235-236:84-92
pubmed: 31101556
Blood. 2009 May 28;113(22):5583-7
pubmed: 19357396
J Biol Chem. 2001 Sep 28;276(39):36779-87
pubmed: 11468284
Front Immunol. 2019 Feb 28;10:116
pubmed: 30891028
Leuk Lymphoma. 2010 Oct;51(10):1931-5
pubmed: 20846103
PLoS Genet. 2017 Aug 7;13(8):e1006925
pubmed: 28787443
Cancer Res. 2018 Dec 15;78(24):6762-6770
pubmed: 30348809
Leukemia. 2004 Sep;18(9):1553-5
pubmed: 15284863
Blood. 2014 Jun 12;123(24):3811-7
pubmed: 24753537
Blood. 2001 Feb 1;97(3):829-30
pubmed: 11227095
Br J Haematol. 2002 Jul;118(1):296-304
pubmed: 12100165
N Engl J Med. 2013 May 9;368(19):1781-90
pubmed: 23656643
Int J Hematol. 2017 Aug;106(2):189-195
pubmed: 28555414
J Exp Med. 2009 Aug 3;206(8):1701-7
pubmed: 19620628
Exp Hematol. 2017 Feb;46:9-20
pubmed: 27789332
EMBO J. 2007 Apr 4;26(7):1782-93
pubmed: 17363902
PLoS Genet. 2016 Aug 04;12(8):e1006236
pubmed: 27490902
Blood. 2004 Aug 1;104(3):667-74
pubmed: 15069015
J Biol Chem. 2018 May 11;293(19):7387-7396
pubmed: 29572350
Blood. 1999 Jan 15;93(2):440-6
pubmed: 9885205
Blood. 2010 Jun 24;115(25):5131-6
pubmed: 20237318
Blood. 1997 Apr 1;89(7):2369-75
pubmed: 9116280
Biochem Biophys Res Commun. 2020 Feb 26;523(1):208-213
pubmed: 31848046
Blood. 2016 Feb 25;127(8):1017-23
pubmed: 26712909
Blood. 2016 Oct 20;128(16):2097-2099
pubmed: 27581359
Leukemia. 2013 Sep;27(9):1870-3
pubmed: 23604229
Blood. 2017 Feb 9;129(6):715-722
pubmed: 28028025
Blood. 2004 Apr 15;103(8):3226-9
pubmed: 15070707
Blood. 1999 Jan 15;93(2):447-58
pubmed: 9885206
J Mol Diagn. 2017 Jan;19(1):43-56
pubmed: 27836695
Cell. 2016 Nov 17;167(5):1415-1429.e19
pubmed: 27863252
Blood. 2015 Oct 8;126(15):1865-7
pubmed: 26324699
Leuk Lymphoma. 2014 Jul;55(7):1661-2
pubmed: 24033109
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3135-40
pubmed: 16492764
Blood. 2004 Jan 15;103(2):571-9
pubmed: 14512302
Leukemia. 2013 Sep;27(9):1946-9
pubmed: 23774674
Clin Cancer Res. 2016 Feb 1;22(3):757-64
pubmed: 26475333
J Mol Diagn. 2018 Jan;20(1):123-125
pubmed: 29249243
Blood. 2009 Jan 15;113(3):668-70
pubmed: 19020310
Blood. 2018 Jan 18;131(3):373
pubmed: 29348313
Nat Biotechnol. 2001 May;19(5):434-9
pubmed: 11329012
Blood. 2019 Sep 12;134(11):867-879
pubmed: 31366621
Blood. 2019 Oct 24;134(17):1441-1444
pubmed: 31484648
Blood. 2014 Apr 3;123(14):2229-37
pubmed: 24523240
Blood Adv. 2020 Mar 24;4(6):1131-1144
pubmed: 32208489
Cancer. 2018 Aug;124(16):3329-3338
pubmed: 29932212
Am J Hematol. 2019 Jul;94(7):757-766
pubmed: 30963592
Genet Mol Biol. 2019;42(1 suppl 1):215-231
pubmed: 31067289
Blood. 2019 Dec 26;134(26):2414-2416
pubmed: 31697825
Sci Rep. 2015 Jan 12;5:7729
pubmed: 25578556

Auteurs

Amy M Trottier (AM)

Section of Hematology/Oncology, Department of Medicine, and.
University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL.

Lawrence J Druhan (LJ)

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC; and.

Ira L Kraft (IL)

Section of Hematology/Oncology, Department of Medicine, and.
University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL.
Internal Medicine-Pediatrics Residency Program, Department of Medicine.

Amanda Lance (A)

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC; and.

Simone Feurstein (S)

Section of Hematology/Oncology, Department of Medicine, and.
University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL.

Maria Helgeson (M)

Department of Human Genetics, and.

Jeremy P Segal (JP)

Department of Pathology, University of Chicago, Chicago, IL.

Soma Das (S)

Department of Human Genetics, and.

Belinda R Avalos (BR)

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC; and.

Lucy A Godley (LA)

Section of Hematology/Oncology, Department of Medicine, and.
University of Chicago Comprehensive Cancer Center, University of Chicago, Chicago, IL.
Department of Human Genetics, and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH